Table 1.
Clinical and demographic characteristics.
| 1 | 2 | 3 | 4 | 5 | |
|---|---|---|---|---|---|
| Age (years) | 66 | 49 | 74 | 79 | 86 |
| Sex | Male | Male | Male | Female | Female |
| Order of Dx | Epilepsy then PD | Epilepsy then PD | Epilepsy then PD | PD then epilepsy | PD then epilepsy |
| Epilepsy duration (years) | 36 | 6 | 50 | 6 | 4 |
| Type of seizures | Complex partial, GTC | Complex partial, secondarily generalized | Complex partial, GTC | Complex partial | Complex partial |
| PD duration (years) | 10 | 1 | 1 | 15 | 10 |
| UPDRS-III at PD Dx | 9.5 | 10 | 21 | 28.5 | 26 |
| H&Y stage at PD Dx | 1 | 1 | 2.5 | 2.5 | 2.5 |
| UPDRS-III at epilepsy Dx | N/A | N/A | N/A | 27 | 21 |
| H&Y stage at epilepsy Dx | N/A | N/A | N/A | 2 | 2 |
| UPDRS-III at last visit | 51 | 23 | 20 | 51 | 36 |
| H&Y stage at last visit | 3 | 2 | 2.5 | 4 | 2 |
| Most recent antiepileptic medication(s) | Eslicarbazepine | Carbamazepine and clonazepam | Carbamazepine | Levetiracetam and lamotrigine | Levetiracetam |
| Most recent LEDD (mg) | 750 | N/A | 390 | 796 | 780 |
Dx, diagnosis; GTC, generalized tonic-clonic; PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease Rating Scale; H&Y, Hoehn and Yahr; N/A, not applicable; LEDD, levodopa equivalent daily dose.